Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, and Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user [Hospitals, Specialty Clinics, and Others], and Regional Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI101009

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 20.1% from 2023-2030
Unit	Value (USD Billion)
Segmentation	By Treatment Modality, End-user, and Geography
By Treatment Modality	Bone Marrow Transplant Blood Transfusion Pharmacotherapy Hydroxyurea Branded Products Endari Adakveo Oxbryta Zynteglo PYRUKYND (Mitapivat) CTX001 Inclacumab MGTA-145 Vamifeport (VIT-2763) ALXN1820 FT-4202 GBT021601
By End-user	Hospitals Specialty Clinics Others
By Geography	U.S. (By Treatment Modality and End-user) Europe (By Treatment Modality, End-user, and Country/Sub-region) Germany U.K. France Italy Spain Scandinavia Rest of Europe Rest of the World (By Treatment Modality, End-user, and Country/Sub-region) India China Japan GCC Countries Rest of ROW